Company Overview and News
* New Pacific Metals Corp - for three months ended September 30, 2017, net loss attributable to equity holders was $0.01 per share Source text for Eikon: Further company coverage:
New Pacific Metals Corp. ("New Pacific" or the "Company") (TSX VENTURE:NUAG) is pleased to announce the appointment of Gordon Neal to the position of President of the Company. Mr. Neal has extensive experience in the metals and mining sector, capital markets and government communications. He was most recently the Vice President of Corporate Development for Silvercorp Metals Inc., New Pacific's largest shareholder.
New Pacific Metals Corp. ("New Pacific" or the "Company") (TSX VENTURE:NUAG) is pleased to announce that it has closed its previously announced private placement (the "Private Placement") of 1,250,000 common shares (the "Shares") at a price of US$0.80 per Share for gross proceeds of US$1,000,000. The proceeds from the Private Placement will be used by the Company for payments to be made in connection with its previously announced acquisition of Empresa Minera Alcira SA.
New Pacific Holdings Corp. ("New Pacific" or the "Company") (TSX VENTURE:NUX) announces that its wholly-owned subsidiary New Pacific Investment Corp. Limited has closed its previously announced acquisition (the "Acquisition") of Empresa Minera Alcira S.A., a private Bolivian incorporated mining company ("Alcira") from its three shareholders (the "Vendors") pursuant to the terms of a share purchase agreement (the "Agreement") dated March 28, 2017.
New Pacific Holdings Corp. ("New Pacific" or the "Company") (TSX VENTURE:NUX) today provided an update on its plans to acquire 100% of a private Bolivian mining company. The Company on April 10, 2017 announced it had signed a binding share purchase agreement dated March 28, 2017 (the "Agreement") to acquire a 100% interest in Empresa Minera Alcira S.A., ("Alcira"). As per the Agreement, the Company has been actively carrying out a confirmation drilling program in Bolivia to twin three drill holes drilled by Alcira in the past on its Silver Sand property.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 12, 2017) - New Pacific Holdings Corp. ("New Pacific" or the "Company") (TSX VENTURE:NUX) today announced its unaudited condensed consolidated interim financial results for the three and nine months ended March 31, 2017.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 13, 2016) - New Pacific Metals Corp. (TSX:NUX) ("New Pacific" or the "Company") announces that it has applied to voluntarily delist its common shares (the "Common Shares") from the Toronto Stock Exchange (the "TSX") and has received conditional approval to list the Common Shares on the TSX Venture Exchange (the "TSX-V"). It is expected that the Common Shares will be delisted from the TSX on or about June 30, 2016, and listed on the TSX-V on or about the same date.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 13, 2016) - New Pacific Metals Corp. ("New Pacific" or the "Company") (TSX:NUX) today announced its unaudited condensed consolidated interim financial results for the three and nine months ended March 31, 2016.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 12, 2016) - New Pacific Metals Corp. (TSX:NUX) ("New Pacific" or the "Company") today announced its unaudited condensed consolidated interim financial results for the three and six months ended December 31, 2015. This earnings release should be read in conjunction with the Company's Management Discussion...
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...